Read by QxMD icon Read

Cutaneous lymphoma

shared collection
172 papers 25 to 100 followers
By Rosa Izu Dermatologist. Associated Professor of Dermatology. Medicine. Basque Country University
Amrita Goyal, Robert E LeBlanc, Joi B Carter
Primary cutaneous B-cell lymphomas are non-Hodgkin lymphomas that present in the skin without evidence of extracutaneous involvement at diagnosis. There are 3 types of primary cutaneous B-cell lymphomas: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg-type. Because it is most frequently diagnosed on skin biopsy, intravascular large B-cell lymphoma is commonly included with pcBCL. A complicating factor in diagnosing primary cutaneous B-cell lymphomas is that they can appear histologically identical to their extracutaneous counterparts...
February 2019: Hematology/oncology Clinics of North America
Sarah Menguy, Marie Beylot-Barry, Parrens Marie, Anne Pham Ledard, Eric Frison, François Comoz, Maxime Battistella, Vanessa Szablewski, Brigitte Balme, Anne Croue, Frédéric Franck, Nicolas Ortonne, Emilie Tournier, Laurence Lamant, Agnès Carlotti, Anne De Muret, François Le Gall, Marie-Hélène Lorton, Jean-Philippe Merlio, Béatrice Vergier
AIMS: We applied the 2017 WHO classification criteria to categorize a series of 64 primary cutaneous large B-cell lymphomas (PCLBCLs), containing a majority (⩾80%) of large-cells and a proliferative rate ⩾40%, raising the problem of the differential diagnosis between PCLBCLs, leg type (PCLBCLs-LT) or primary cutaneous follicle center lymphomas with large cell morphology (PCFCLs-LC). The aims were to determine reproducibility and prognostic relevance of the 2017 WHO criteria. METHODS AND RESULTS: Morphology and phenotype identified 32 PCLBCLs-LT and 25 PCFCLs-LC; 7 cases (11%) remained unclassified...
February 4, 2019: Histopathology
Adele de Masson, Jean-David Bouaziz, Caroline Ram-Wolff, Pauline Brice, Isabelle Moulonguet, Marie-Dominique Vignon-Pennamen, Florian Herms, Laurence Verneuil, Jacqueline Rivet, Martine Bagot, Maxime Battistella
Primary cutaneous follicle center lymphoma (PCFCL) is the most frequent primary cutaneous B-cell lymphoma. It presents usually with erythematous papules, plaques and tumors that predominate on the head, neck and upper trunk. The evolution is indolent but relapses are frequent. Atypical presentations of PCFCL have been occasionally described, such as diffuse facial erythema, one case of scarring alopecia (1), macular lesions, including 2 cases of scarring alopecia (2), miliary agminated papules (3), or extensive telangiectasia of the scalp (4)...
February 4, 2019: Journal of the European Academy of Dermatology and Venereology: JEADV
Erin Grinich, Stephanie Mengden Koon, Michael J Cascio, Nicole Fett
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare condition that falls underneath the umbrella of primary cutaneous T-cell lymphomas (CTCLs). SPTCL can be very difficult to diagnose as it may mimic other subtypes of CTCL, such as γ/δ T-cell lymphoma (TCL), or other forms of panniculitis. Confirmation of diagnosis often requires immunohistochemical analysis and is essential for proper prognosis and therapeutic management. Herein, we present a case of SPTCL that mimicked lupus panniculitis and was successfully treated with prednisone taper and methotrexate...
September 15, 2018: Dermatology Online Journal
Natalia Buchely, Rami N Al-Rohil, Phyu P Aung, George Jour, Carlos Torres-Cabala, Victor G Prieto, Doina Ivan
Mycosis fungoides (MF) is the most common variant of cutaneous T-cell lymphomas. Large-cell transformation of MF has been associated with disease progression and overall poor outcome. The expression of CD30, which defines anaplastic large cell lymphoma (ALCL) and lymphomatoid papulosis, might also occur in a subset of patients with MF, with or without large-cell transformation. Brentuximab vedotin is an anti-CD30 monoclonal antibody which has been proven to be a safe and effective therapeutic agent in the treatment of CD30-positive lymphomas, such as Hodgkin lymphoma and ALCL...
May 27, 2018: Journal of Cutaneous Pathology
Leonie Brockmann, Shiwa Soukou, Babett Steglich, Paulo Czarnewski, Lilan Zhao, Sandra Wende, Tanja Bedke, Can Ergen, Carolin Manthey, Theodora Agalioti, Maria Geffken, Oliver Seiz, Sara M Parigi, Chiara Sorini, Jens Geginat, Keishi Fujio, Thomas Jacobs, Thomas Roesch, Jacob R Izbicki, Ansgar W Lohse, Richard A Flavell, Christian Krebs, Jan-Ake Gustafsson, Per Antonson, Maria Grazia Roncarolo, Eduardo J Villablanca, Nicola Gagliani, Samuel Huber
IL-10 is a prototypical anti-inflammatory cytokine, which is fundamental to the maintenance of immune homeostasis, especially in the intestine. There is an assumption that cells producing IL-10 have an immunoregulatory function. However, here we report that IL-10-producing CD4+ T cells are phenotypically and functionally heterogeneous. By combining single cell transcriptome and functional analyses, we identified a subpopulation of IL-10-producing Foxp3neg CD4+ T cells that displays regulatory activity unlike other IL-10-producing CD4+ T cells, which are unexpectedly pro-inflammatory...
December 21, 2018: Nature Communications
Xuesong Wu, Daniel K Hsu, Kang-Hsin Wang, Yuanshen Huang, Lindsay Mendoza, Youwen Zhou, Sam T Hwang
A crucial question pertains to a role of IL-10 as a tumorigenic factor, or just a marker of advanced disease in cutaneous T-cell lymphoma (CTCL). Herein, we measured significantly elevated IL-10 mRNA in a cohort of skin samples of patients with CTCL. Increased IL-10 was also detected in the tumor microenvironment of an established inflammation-dependent murine model of using MBL2 T lymphoma cells. Conditioned media from MBL2 cells was able to stimulate IL-10 production in bone marrow-derived macrophages in an IL-4-dependent manner...
October 2, 2018: Leukemia & Lymphoma
Macartney Welborn, Madeleine Duvic
Cutaneous T-cell lymphomas (CTCLs) are a group of non-Hodgkin's lymphomas that present in the skin. In early-stage disease, the course is generally chronic and indolent; however, in advanced stages of disease, therapies rarely provide long-lasting responses, and the only potential curative therapy is allogeneic hematopoietic stem-cell transplantation. This has led to the search for novel targeted therapies to better treat more advanced stages of CTCLs that cannot be controlled by typical treatment regimens...
February 2019: American Journal of Clinical Dermatology
Ahmed Farhan, Elise A Chong, Stephen J Schuster, Lauren Strelec, Sunita Dwivedy Nasta, Daniel Landsburg, Jakub Svoboda
BACKGROUND: Peripheral T-cell lymphomas (PTCLs) are generally aggressive non-Hodgkin lymphomas that portend poor prognosis with currently available therapies. Bexarotene, a retinoic acid derivative, has efficacy in cutaneous T-cell lymphomas, but its activity in PTCL is unknown. PATIENTS AND METHODS: We conducted a retrospective, single-institution, review of off-label bexarotene therapy in patients with PTCL between 2005 and 2016. RESULTS: Twelve patients were treated with bexarotene as monotherapy: 3 patients with PTCL, not otherwise specified, and 9 patients with angioimmunoblastic T-cell lymphoma...
February 2019: Clinical Lymphoma, Myeloma & Leukemia
Jose Candido Caldeira Xavier Júnior, Juliana Polizel Ocanha-Xavier
Recently, the World Health Organization published the revised 4th edition of its classification of tumors of hematopoietic and lymphoid tissues. The present paper is a concise comparative review of the main primary cutaneous T-cell hematopoietic tumors, with emphasis on their immunohistochemical profiles.
November 2018: Anais Brasileiros de Dermatologia
Stacey McCaffrey, Ryan A Black, Mitchell Nagao, Marjan Sepassi, Gaurav Sharma, Susan Thornton, Youn H Kim, Julia Braverman
BACKGROUND: Although the quality of life (QoL) plays an important role in treatment decision making and clinical management of mycosis fungoides (MF) or Sézary syndrome (SS) subtypes of cutaneous T-cell lymphomas (MF/SS-CTCLs), an MF- or SS-specific measure of QoL does not exist. OBJECTIVE: The objective of this research was to develop and validate the first QoL instrument for MF/SS-CTCL using a patient-centered approach. METHODS: A conceptual framework for the MF/SS-CTCL QoL was developed through a literature review and interviews with key opinion leaders...
January 7, 2019: Journal of Medical Internet Research
Rein Willemze, Lorenzo Cerroni, Werner Kempf, Emilio Berti, Fabio Facchetti, Steven H Swerdlow, Elaine S Jaffe
Primary cutaneous lymphomas are a heterogeneous group of T-cell lymphomas and B-cell lymphomas that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. In the last decade the 2005 WHO-EORTC consensus classification has served as a golden standard for the diagnosis and classification of these conditions. In September 2018 an updated version of the WHO-EORTC was published in the 4th edition of the WHO classification for Skin Tumours Blue Book. In this classification primary cutaneous acral CD8+ T-cell lymphoma and EBV-positive mucocutaneous ulcer are included as new provisional entities, and a new section on cutaneous forms of chronic active EBV disease has been added...
January 11, 2019: Blood
William T Johnson, Reetu Mukherji, Saritha Kartan, Neda Nikbakht, Pierluigi Porcu, Onder Alpdogan
Mycosis fungoides and Sézary syndrome encompass over 70% of all cases of cutaneous T-cell lymphoma (CTCL). While early stage disease has excellent long-term survival rates, advanced stage disease (IIB-IV) carries a poor prognosis with a median 5-year overall survival rate of approximately 50%. Early stage and advanced stage disease have different treatment algorithms with systemic therapy being indicated upfront in the later. The role of allogeneic hematopoietic stem cell transplant (HSCT) has gained considerable interest in recent years as a treatment option for CTCL given the increasingly promising long-term outcomes in an otherwise incurable disease...
October 19, 2018: Chinese Clinical Oncology
J Yoo, F Shah, S Velangi, G Stewart, J S Scarisbrick
Secukinumab is an interleukin (IL)-17 monoclonal antibody inhibiting T-helper (Th)1-mediated immune response. It has proven high efficacy for moderate to severe psoriasis but data on its long-term toxicities are limited. We describe two patients who received secukinumab for clinically presumed psoriasis, but were subsequently diagnosed with mycosis fungoides (MF) following skin biopsies triggered by skin deterioration while on secukinumab. Previous studies suggested decreased numbers of regulatory T cells (Tregs) with increasing stage of MF, which may lead to the shift in the Treg/Th17 balance towards the Th17 pathway...
October 4, 2018: Clinical and Experimental Dermatology
Lei Zhao, Jean-Phillip Okhovat, Eric K Hong, Youn H Kim, Gary S Wood
Advanced-stage cutaneous T-cell lymphoma (CTCL) is usually a fatal malignancy despite optimal use of currently available treatments. In this preclinical study of novel CTCL therapy, we performed in vitro and ex vivo experiments to determine the efficacy of combination treatment with a panel of BET bromodomain inhibitors (BETi) (JQ1, OTX015, CPI-0610, I-BET762) and HDAC inhibitors (HDACi) (SAHA/Vorinostat, Romidepsin). BETi/HDACi combinations were synergistic (combination index <1) against cell viability and induced G0/G1 cell cycle arrest...
January 2019: Neoplasia: An International Journal for Oncology Research
Mudit Chowdhary, Andrew Song, Nicholas G Zaorsky, Wenyin Shi
Cutaneous T-cell lymphoma is a rare group of malignancies characterized by the proliferation of CD4+ T-cells, of which mycosis fungoides (MF) is the predominant subtype. The neoplastic lymphocytes of MF are extremely radiosensitive and even low doses of radiation can produce excellent responses. As such, radiotherapy (RT) is considered to be the most efficacious single agent treatment option for MF. Total skin electron beam therapy (TSEBT) is a special RT technique that allows for homogenous irradiation of the entire skin...
September 17, 2018: Chinese Clinical Oncology
Marie-Louise Lovgren, Julia J Scarisbrick
Mycosis fungoides (MF) represents the majority of the primary cutaneous T-cell lymphomas (CTCL). Most have early stage MF with localised patches and plaques, which has a favourable survival outcome, but nearly a quarter progress to late stage with tumours, erythroderma, and systemic involvement. Management is based on stage directed treatment with early stage MF (IA-IIA) using skin directed therapies (SDTs), including topical corticosteroids (TCS), chlormethine or retinoids, phototherapy, and radiotherapy (localised or total skin electron beam therapy)...
November 28, 2018: Chinese Clinical Oncology
Cecilia Larocca, Thomas Kupper
Cutaneous T-cell lymphomas are a heterogeneous collection of non-Hodgkin lymphomas that arise from skin-tropic memory T lymphocytes. Among them, mycosis fungoides (MF) and Sézary syndrome (SS) are the most common malignancies. Diagnosis requires the combination of clinical, pathologic, and molecular features. Significant advances have been made in understanding the genetic and epigenetic aberrations in SS and to some extent in MF. Several prognostic factors have been identified. The goal of treatment is to minimize morbidity and limit disease progression...
February 2019: Hematology/oncology Clinics of North America
Ce Tiffon, Je Adams, L van der Fits, S Wen, Pa Townsend, A Ganesan, E Hodges, Mh Vermeer, G Packham
BACKGROUND AND PURPOSE: Vorinostat and romidepsin are histone deacetylase inhibitors (HDI), approved for the treatment of cutaneous T-cell lymphoma (CTCL). However, the mechanism(s) by which these drugs exert their anti-cancer effects are not fully understood. Since CTCL is associated with immune dysregulation, we investigated whether these HDI modulated cytokine expression in CTCL cells. EXPERIMENTAL APPROACH: CTCL cell lines and primary CTCL cells were treated in vitro with vorinostat or romidepsin, or with STAT3 pathway inhibitors...
April 2011: British Journal of Pharmacology
M N Lowe, G L Plosker
Bexarotene is a selective retinoid X receptor (RXR) agonist. It binds to, and activates RXRs which function as ligand-activated transcription factors that control gene expression. This leads to modulation of cell growth, apoptosis, and differentiation. In patients with refractory or persistent early stage cutaneous T cell lymphoma (CTCL), the overall response rate was 54% after oral bexarotene 300 mg/m2/day. The overall response rate in patients with refractory or persistent advanced stage CTCL was 45% at the same dosage...
July 2000: American Journal of Clinical Dermatology
2018-04-05 16:15:16
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"